Overview

* Medpace ( MEDP ) Q3 revenue grows 23.7% yr/yr, beating analyst expectations

* Net income for Q3 rises, but net income margin decreases compared to last year

* Company repurchased 14,649 shares for $4.5 mln in Q3 2025

Outlook

* Medpace ( MEDP ) forecasts 2025 revenue between $2.480 bln and $2.530 bln

* Medpace ( MEDP ) expects 2025 GAAP net income between $431 mln and $439 mln

* Medpace ( MEDP ) anticipates 2025 EBITDA between $545 mln and $555 mln

Result Drivers

* NET NEW BUSINESS AWARDS - Medpace ( MEDP ) reports a 47.9% increase in net new business awards, contributing to revenue growth

* BACKLOG CONVERSION - Co achieved a backlog conversion rate of 23.0%, supporting revenue growth

* NET BOOK-TO-BILL RATIO - Medpace ( MEDP ) maintains a net book-to-bill ratio of 1.20x, indicating strong demand

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $659.90 $640.99

Revenue mln mln (9

Analysts

)

Q3 EPS $3.86

Q3 Net $111.13

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Medpace Holdings Inc ( MEDP ) is $450.00, about 21.3% below its October 21 closing price of $545.64

* The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)